Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
MLYS
MLYS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MLYS News
FDA Accepts Marketing Application for Mineralys' Lorundrostat
7h ago
seekingalpha
Mineralys Therapeutics' NDA for Lorundrostat Accepted by FDA
16h ago
NASDAQ.COM
FDA Accepts Mineralys' NDA for Lorundrostat Targeting Hypertension
1d ago
Newsfilter
Chronic Kidney Disease Market Growth Drivers
Mar 03 2026
Newsfilter
MLYS Stock 52-Week Highs and Lows Analysis
Feb 13 2026
NASDAQ.COM
Mineralys Grants Stock Options to New Employees
Feb 12 2026
Newsfilter
Medical Properties Trust Options Volume Surges 120.3% Today
Jan 07 2026
NASDAQ.COM
Mineralys Highlights Lorundrostat Clinical Progress, Anticipates 2026 Data Release
Jan 06 2026
Globenewswire
Mineralys Therapeutics (MLYS) Shares Oversold with RSI at 29.3
Dec 30 2025
NASDAQ.COM
Mineralys Therapeutics Inc Offers 16.1% Annualized Return on $22.50 Put Option
Dec 29 2025
NASDAQ.COM
UnitedHealth Group Options Volume Surges to 67,042 Contracts
Dec 26 2025
NASDAQ.COM
Mineralys Therapeutics Shares Surge 203.4%, NDA Submission Expected in 2026
Dec 26 2025
NASDAQ.COM
Suvretta Capital Increases Mineralys Stake by 387,641 Shares Worth $57.25 Million
Dec 23 2025
Fool
Suvretta Capital Increases MLYS Stake by 387,641 Shares, Valued at $57.25 Million
Dec 23 2025
NASDAQ.COM
Mineralys' Lorundrostat for Treatment-Resistant Hypertension Recognized by JAMA as Key Study
Dec 12 2025
Globenewswire
Mineralys' lorundrostat for Treatment-Resistant Hypertension Recognized by JAMA as Key Research of 2025
Dec 12 2025
Newsfilter
Show More News
